Tassos Gianakakos

Tassos Gianakakos is the co-founder, chairman, and CEO of Prolaio, a connected platform for heart care that utilizes remote monitoring, AI-powered predictive analytics, and user-friendly experiences to drive optimal treatment plans and outcomes. Prior to Prolaio, Tassos served as the Chief Executive Officer of MyoKardia, a company focused on developing therapies for cardiovascular diseases that was acquired by BMS in November 2020. Tassos has also held senior roles at MAP Pharmaceuticals, Codexis, Maxygen, and Merck. He holds degrees in Chemical Engineering, Economics, Biotechnology, and an MBA from prestigious institutions such as MIT, Northwestern University, and Harvard Business School.